INTERNAL REGULATIONS OF THE BOARD OF DIRECTORS  |
Emmanuel Huynh
Chairman
Emmanuel Huynh holds a Master's degree in Business Administration from Sciences Po Paris and a PhD in Political Sciences from the Sorbonne University. He is Partner and Managing Director of NewCap, an investor relations and financial communication consulting firm. He began his career in investment banking and financial management for large groups. He is also General Delegate of Club F, the first think tank dedicated to the Family Office in France.
Chairman
Emmanuel Huynh holds a Master's degree in Business Administration from Sciences Po Paris and a PhD in Political Sciences from the Sorbonne University. He is Partner and Managing Director of NewCap, an investor relations and financial communication consulting firm. He began his career in investment banking and financial management for large groups. He is also General Delegate of Club F, the first think tank dedicated to the Family Office in France.
Cyrille Tupin, C.P.A.
CEO
Mr. Tupin was previously Audit Director of Sygnatures, the largest private audit and consulting company in Toulouse, France. He spent more than seven years at PriceWaterhouseCoopers with 2 years of international experience in Canada. He has worked on a number of high-profile business transactions, including the Alcan Group takeover bid for Pechiney and the consolidation audit of Pechiney for Alcan. Mr. Tupin has been a French C.P.A. since 2002.
CEO
Mr. Tupin was previously Audit Director of Sygnatures, the largest private audit and consulting company in Toulouse, France. He spent more than seven years at PriceWaterhouseCoopers with 2 years of international experience in Canada. He has worked on a number of high-profile business transactions, including the Alcan Group takeover bid for Pechiney and the consolidation audit of Pechiney for Alcan. Mr. Tupin has been a French C.P.A. since 2002.
Christian Chavy
Chief Executive Officer of Stallergenes Christian Chavy brings substantial pharma and biotech management experience to the Board. Mr. Chavy is currently CEO and Board member of MedDay Pharmaceuticals. From 2014 to March 2016, he was Chief Executive Officer of Stallergenes. In 2010, Mr. Chavy joined ARES Life Science, an investment fund dedicated to healthcare. Previously, he served as President of Global Operations for Actelion Pharmaceuticals. Prior to joining Actelion, he was Vice President at Serono’s reproductive medicine strategic unit in Geneva and Chairman of Serono’s French subsidiary. He also spent five years at Groupe Rhône Poulenc Rorer as its Chairman in Canada, having previously been Chairman and CEO of Rorer France. Christian CHAVY has graduated from ESSEC and from the Institut de Contrôle de Gestion of Paris (ICG).
Chief Executive Officer of Stallergenes Christian Chavy brings substantial pharma and biotech management experience to the Board. Mr. Chavy is currently CEO and Board member of MedDay Pharmaceuticals. From 2014 to March 2016, he was Chief Executive Officer of Stallergenes. In 2010, Mr. Chavy joined ARES Life Science, an investment fund dedicated to healthcare. Previously, he served as President of Global Operations for Actelion Pharmaceuticals. Prior to joining Actelion, he was Vice President at Serono’s reproductive medicine strategic unit in Geneva and Chairman of Serono’s French subsidiary. He also spent five years at Groupe Rhône Poulenc Rorer as its Chairman in Canada, having previously been Chairman and CEO of Rorer France. Christian CHAVY has graduated from ESSEC and from the Institut de Contrôle de Gestion of Paris (ICG).
Laura A. Coruzzi, Ph.D., J.D.
Senior Vice President, Intellectual Property
REGENXBIO Inc. Dr. Laura A. Coruzzi is the Senior Vice President of Intellectual Property at REGENXBIO. Prior to joining REGENXBIO, Dr. Coruzzi was a partner in the Intellectual Property practice at Jones Day, an international law firm. Previously, she was a partner at Pennie & Edmonds, LLP and was one of the first members of the firm's biotechnology group department founded by S. Leslie Misrock, affectionately known as the "father of biotechnology patent law.” Dr. Coruzzi represented biotechnology and pharmaceutical clients for over 30 years, focusing on strategic planning and management of patent portfolios designed to protect emerging new technologies as well as mature biologic and pharmaceutical therapeutics and diagnostics. She counseled clients on portfolio evaluation, due diligence investigations, patent prosecution and interferences, European oppositions, and licensing in a variety of disciplines including genetic engineering, virology, and biologic and small molecule therapeutics. Her practice also encompassed patent litigation and appeals before the USPTO Board of Appeals and the Federal Circuit, where she and her team won reversal of an $18 million jury verdict in 2000 for Cadus Pharmaceutical Corporation in a case involving cell-based assays for drug screening. More recently, she was a member of the team representing Myriad in Association for Molecular Pathology v. Myriad Genetics (U.S. Supreme Court 2013).
Dr. Coruzzi received her J.D. from Fordham University School of Law, earned her Ph.D. in Biology at Fordham University and completed a post-doctoral fellowship at the Mount Sinai School of Medicine before entering the practice of law.
Senior Vice President, Intellectual Property
REGENXBIO Inc. Dr. Laura A. Coruzzi is the Senior Vice President of Intellectual Property at REGENXBIO. Prior to joining REGENXBIO, Dr. Coruzzi was a partner in the Intellectual Property practice at Jones Day, an international law firm. Previously, she was a partner at Pennie & Edmonds, LLP and was one of the first members of the firm's biotechnology group department founded by S. Leslie Misrock, affectionately known as the "father of biotechnology patent law.” Dr. Coruzzi represented biotechnology and pharmaceutical clients for over 30 years, focusing on strategic planning and management of patent portfolios designed to protect emerging new technologies as well as mature biologic and pharmaceutical therapeutics and diagnostics. She counseled clients on portfolio evaluation, due diligence investigations, patent prosecution and interferences, European oppositions, and licensing in a variety of disciplines including genetic engineering, virology, and biologic and small molecule therapeutics. Her practice also encompassed patent litigation and appeals before the USPTO Board of Appeals and the Federal Circuit, where she and her team won reversal of an $18 million jury verdict in 2000 for Cadus Pharmaceutical Corporation in a case involving cell-based assays for drug screening. More recently, she was a member of the team representing Myriad in Association for Molecular Pathology v. Myriad Genetics (U.S. Supreme Court 2013).
Dr. Coruzzi received her J.D. from Fordham University School of Law, earned her Ph.D. in Biology at Fordham University and completed a post-doctoral fellowship at the Mount Sinai School of Medicine before entering the practice of law.
Karen Noël
General Partner, Partech Ventures Karen Noël, Lawyer is General Partner at Partech Ventures since January 2017, the investment fund specializing in digital technology and new technologies, spread over three offices namely San Francisco, Paris and Berlin.
General Partner, Partech Ventures Karen Noël, Lawyer is General Partner at Partech Ventures since January 2017, the investment fund specializing in digital technology and new technologies, spread over three offices namely San Francisco, Paris and Berlin.
Previously with Gide, Karen Noël, M & A specialist, fund raising and IPOs, operates in the digital, new technologies and biotechnology sectors. She has special experience with seed and venture funds as part of their investments in start-ups, which she has carried out many times, notably for DBV, ManoMano, Teads and Sigfox. In particular, she advised Goldman Sachs, JP Morgan, Citigroup and William Blair during the introduction of Nasdaq. She also intervened in the fundraising campaigns of DBV and MedDay Pharmaceuticals. Karen Noël, a graduate of Essec and Paris II Panthéon-Assas University, began her career at De Pardieu Brocas Maffei and then joined Morgan Lewis where she worked for nearly ten years as a partner before joining Gide in November 2013.
Jean-Gérard Galvez
Director
After some fifteen years with major groups (Dupont de Nemours, Control Data), Jean-Gérard Galvez left Control Data's international operations in 1994 to become Chairman & CEO of ActivCard, a French Internet security start-up. He expanded the company into the United States, listing it on the Nasdaq in 2000 at a valuation of over $2 billion. He managed the company until 2003.
A private investor and Senior Advisor to investment funds since 2004 (Natixis/Seventure Partners; CVC Growth Partners; Téthys Invest), he has been a member of the Board of Directors of a dozen listed and private companies, including 6 terms as Chairman of the Board. He has led a large number of fund-raisings, participated in two IPOs, and accompanied several M&A operations in the software and healthcare sectors. He is currently a director of 4 companies, and co-founder and director of Exotec (robotics), which recently raised €300m at a valuation of €2 billion.
Jean-Gérard holds an engineering degree from the École Nationale Supérieure des Industries Chimiques, a DEA in management and an MBA from the Stanford Executive Program.
Director
After some fifteen years with major groups (Dupont de Nemours, Control Data), Jean-Gérard Galvez left Control Data's international operations in 1994 to become Chairman & CEO of ActivCard, a French Internet security start-up. He expanded the company into the United States, listing it on the Nasdaq in 2000 at a valuation of over $2 billion. He managed the company until 2003.
A private investor and Senior Advisor to investment funds since 2004 (Natixis/Seventure Partners; CVC Growth Partners; Téthys Invest), he has been a member of the Board of Directors of a dozen listed and private companies, including 6 terms as Chairman of the Board. He has led a large number of fund-raisings, participated in two IPOs, and accompanied several M&A operations in the software and healthcare sectors. He is currently a director of 4 companies, and co-founder and director of Exotec (robotics), which recently raised €300m at a valuation of €2 billion.
Jean-Gérard holds an engineering degree from the École Nationale Supérieure des Industries Chimiques, a DEA in management and an MBA from the Stanford Executive Program.
Luc Demarre
Director
Luc Demarre, born on January 5, 1966 in Paris, is a recognized professional in the financial sector, with 35 years' experience in investment banking. An expert in mergers & acquisitions, fund-raising and restructuring, he has advised major groups, agricultural cooperatives, family shareholders, ETIs and investment funds throughout his career.
After graduating from Paris-Dauphine University with a post-graduate diploma in finance in 1989, Luc began his career at Banque Paribas, where he worked as an M&A analyst in London. In 1991, he joined Deutsche Morgan Grenfell, where he spent eight years as an M&A banker in London and Paris. In 1999, he joined Crédit Suisse First Boston (CSFB) as Head of Investment Banking, where he oversaw the execution and origination of M&A transactions for international clients. His growing experience in this field led him in 2004 to co-found Bucéphale Finance, an independent company specializing in financial advisory services for M&A, restructuring and capital raising. He held the position of Managing Director for over 15 years, during which time he consolidated his reputation for providing strategic support to companies. In 2018, Bucéphale Finance split into two separate entities and Luc co-founded a new independent consulting firm in Paris with one of his two younger partners, specializing in M&A and fundraising operations for major groups,
Director
Luc Demarre, born on January 5, 1966 in Paris, is a recognized professional in the financial sector, with 35 years' experience in investment banking. An expert in mergers & acquisitions, fund-raising and restructuring, he has advised major groups, agricultural cooperatives, family shareholders, ETIs and investment funds throughout his career.
After graduating from Paris-Dauphine University with a post-graduate diploma in finance in 1989, Luc began his career at Banque Paribas, where he worked as an M&A analyst in London. In 1991, he joined Deutsche Morgan Grenfell, where he spent eight years as an M&A banker in London and Paris. In 1999, he joined Crédit Suisse First Boston (CSFB) as Head of Investment Banking, where he oversaw the execution and origination of M&A transactions for international clients. His growing experience in this field led him in 2004 to co-found Bucéphale Finance, an independent company specializing in financial advisory services for M&A, restructuring and capital raising. He held the position of Managing Director for over 15 years, during which time he consolidated his reputation for providing strategic support to companies. In 2018, Bucéphale Finance split into two separate entities and Luc co-founded a new independent consulting firm in Paris with one of his two younger partners, specializing in M&A and fundraising operations for major groups,
Caroline DeSurmontDirector
Senior Executive, with over 25 years' experience in education, biotechnology and industry. Successful experience in managing production, research and development programs, including 4 years of project management and over 20 years of regulatory expertise.
After Servier and Gencell/Serono, Caroline joined Centelion, an Aventis legacy company, in January 2003 as Project Director, then joined Sanofi's Regulatory Affairs group in December 2004 where she held several positions of increasing responsibility in regulatory development and transformation.
For the past 2 years, she has shifted her career towards corporate governance, taking on the position of Secretary of the Company and of Sanofi's Board of Directors.
In her current role, she oversees the work of the directors, coordinating and ensuring the smooth running of the Board of Directors and the Annual General Meeting. She manages and supports the advisory committees (Strategy Committee, Compensation Committee, Appointments, Governance and CSR Committee, and Scientific Committee), and prepares and organizes roadshows, shareholders' meetings and their follow-up.
As Chief of Staff to the Chairman, she ensures smooth relations between the Board of Directors and the Executive Committee.
Caroline is Ph.D, Cardiovascular and Gene Therapy, holds a degree in Project Management from HEC, an MBA from London Business School, an MBA from IMD Business School Lausane and an Executive MBA from Ecole Polytechnique.
After Servier and Gencell/Serono, Caroline joined Centelion, an Aventis legacy company, in January 2003 as Project Director, then joined Sanofi's Regulatory Affairs group in December 2004 where she held several positions of increasing responsibility in regulatory development and transformation.
For the past 2 years, she has shifted her career towards corporate governance, taking on the position of Secretary of the Company and of Sanofi's Board of Directors.
In her current role, she oversees the work of the directors, coordinating and ensuring the smooth running of the Board of Directors and the Annual General Meeting. She manages and supports the advisory committees (Strategy Committee, Compensation Committee, Appointments, Governance and CSR Committee, and Scientific Committee), and prepares and organizes roadshows, shareholders' meetings and their follow-up.
As Chief of Staff to the Chairman, she ensures smooth relations between the Board of Directors and the Executive Committee.
Caroline is Ph.D, Cardiovascular and Gene Therapy, holds a degree in Project Management from HEC, an MBA from London Business School, an MBA from IMD Business School Lausane and an Executive MBA from Ecole Polytechnique.
Olivier Martinez, Ph.D., M.B.A.
Representative of Bpifrance's participation, censor
Representative of Bpifrance's participation, censor
Olivier Martinez is Investment Director in the Life Sciences Division of Bpifrance. Prior to that, Olivier was an Investment Director within CDC Entreprises (2010-2013) and Partner of Bioam Gestion (2000-2010). Olivier Martinez also sits on the boards of Adocia (ADOC, Euronext), Fab Pharma, Genticel (GTCL, Euronext), Poxel (POXEL, Euronext), Innate Pharma (IPH, Euronext), and Alizé Pharma. He is an alumnus of the Ecole Normale Supérieure and holds a PhD in cell biology from the University of Paris XI and a MBA from the Collège des Ingénieurs.